These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2974424

  • 1. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
    [Abstract] [Full Text] [Related]

  • 2. [Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity].
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Nihon Gan Chiryo Gakkai Shi; 1989 May 20; 24(5):1007-14. PubMed ID: 2528599
    [Abstract] [Full Text] [Related]

  • 3. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H, Aoki H, Yoshioka T, Tomita S, Ikegami R, Hamaoka T.
    J Immunol; 1984 Jul 20; 133(1):509-14. PubMed ID: 6233375
    [Abstract] [Full Text] [Related]

  • 4. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells.
    Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T.
    Eur J Immunol; 1984 Sep 20; 14(9):839-43. PubMed ID: 6236991
    [Abstract] [Full Text] [Related]

  • 5. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T.
    J Immunol; 1985 Jan 20; 134(1):108-13. PubMed ID: 3155458
    [Abstract] [Full Text] [Related]

  • 6. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T, Fujiwara H, Mizushima Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1986 Dec 20; 77(6):1267-72. PubMed ID: 2948049
    [Abstract] [Full Text] [Related]

  • 7. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.
    J Immunol; 1984 Mar 20; 132(3):1571-7. PubMed ID: 6198397
    [Abstract] [Full Text] [Related]

  • 8. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T.
    J Immunol; 1986 Apr 01; 136(7):2715-9. PubMed ID: 3005417
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy of tumor-bearing mice utilizing virus help.
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Cancer Immunol Immunother; 1988 Apr 01; 27(3):223-7. PubMed ID: 3263207
    [Abstract] [Full Text] [Related]

  • 10. The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells.
    Sato S, Fukuzawa M, Nakajima H, Ogata M, Kosugi A, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1985 Nov 01; 76(11):1099-106. PubMed ID: 2935516
    [Abstract] [Full Text] [Related]

  • 11. The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Shimizu Y, Takai Y, Wakamiya N, Ueda S, Kato S, Hamaoka T.
    Eur J Immunol; 1984 Feb 01; 14(2):171-5. PubMed ID: 6199215
    [Abstract] [Full Text] [Related]

  • 12. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep 01; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 13. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H, Kawanishi Y, Tsuchida T, Hamaoka T.
    Jpn J Cancer Res; 1986 Feb 01; 77(2):182-9. PubMed ID: 3082830
    [Abstract] [Full Text] [Related]

  • 14. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
    Takatsu K, Hamaoka T, Tominaga A, Kanamasa Y.
    J Immunol; 1980 Dec 01; 125(6):2367-73. PubMed ID: 6776192
    [Abstract] [Full Text] [Related]

  • 15. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism].
    Kosugi A, Fujiwara H, Hamaoka T.
    Gan To Kagaku Ryoho; 1984 Aug 01; 11(8):1527-35. PubMed ID: 6236750
    [Abstract] [Full Text] [Related]

  • 16. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
    Ueda S, Wakamiya N, Wu KS, Kato S, Fujiwara H, Hamaoka T.
    Biken J; 1984 Mar 01; 27(1):1-7. PubMed ID: 6385960
    [Abstract] [Full Text] [Related]

  • 17. [The augmentation of tumor-specific immunity by T-T cell interaction].
    Fujiwara H, Takai Y, Fukuzawa M, Yoshioka T, Izumi Y, Mizushima Y, Qian J, Ogata M, Kosugi A, Nakajima H.
    Gan To Kagaku Ryoho; 1985 Mar 01; 12(3 Pt 2):734-40. PubMed ID: 3157349
    [Abstract] [Full Text] [Related]

  • 18. [Future perspectives on tumor-specific immunotherapy using hapten-reactive T cell activity].
    Hamaoka T.
    Gan To Kagaku Ryoho; 1989 Apr 01; 16(4 Pt 2-1):886-96. PubMed ID: 2786376
    [Abstract] [Full Text] [Related]

  • 19. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
    Shima J, Yoshioka T, Kosugi A, Ogata M, Fujiwara H, Hamaoka T, Ueda S, Kato S.
    Biken J; 1987 Mar 01; 30(1):1-8. PubMed ID: 2445335
    [Abstract] [Full Text] [Related]

  • 20. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T, Shu S.
    J Immunol; 1987 Sep 15; 139(6):2103-9. PubMed ID: 2957448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.